Medicus Pharma’s (MDCX) Buy Rating Reaffirmed at D. Boral Capital

Medicus Pharma (NASDAQ:MDCX)‘s stock had its “buy” rating reissued by equities research analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $14.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 227.87% from the company’s current price.

Separately, D Boral Capital raised Medicus Pharma to a “strong-buy” rating in a research note on Monday, April 14th.

Medicus Pharma Trading Up 8.1 %

NASDAQ MDCX traded up $0.32 on Monday, hitting $4.27. The stock had a trading volume of 34,283 shares, compared to its average volume of 51,430. The firm’s 50-day simple moving average is $3.58. Medicus Pharma has a one year low of $1.80 and a one year high of $6.00.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.14. As a group, equities research analysts expect that Medicus Pharma will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Medicus Pharma stock. Interchange Capital Partners LLC bought a new position in shares of Medicus Pharma Ltd. (NASDAQ:MDCX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 1,457,165 shares of the company’s stock, valued at approximately $3,628,000. Medicus Pharma accounts for about 1.3% of Interchange Capital Partners LLC’s investment portfolio, making the stock its 15th largest holding. Interchange Capital Partners LLC owned approximately 13.43% of Medicus Pharma at the end of the most recent quarter.

Medicus Pharma Company Profile

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.